U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Reeves BC, Scott LJ, Taylor J, et al. The Effectiveness, cost-effectiveness and acceptability of Community versus Hospital Eye Service follow-up for patients with neovascular age-related macular degeneration with quiescent disease (ECHoES): a virtual randomised balanced incomplete block trial. Southampton (UK): NIHR Journals Library; 2016 Oct. (Health Technology Assessment, No. 20.80.)

Cover of The Effectiveness, cost-effectiveness and acceptability of Community versus Hospital Eye Service follow-up for patients with neovascular age-related macular degeneration with quiescent disease (ECHoES): a virtual randomised balanced incomplete block trial

The Effectiveness, cost-effectiveness and acceptability of Community versus Hospital Eye Service follow-up for patients with neovascular age-related macular degeneration with quiescent disease (ECHoES): a virtual randomised balanced incomplete block trial.

Show details

References

1.
National Institute for Health and Care Excellence (NICE). Ranibizumab and Pegaptanib for the Treatment of Age-Related Macular Degeneration. London: NICE; 2008.
2.
Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419–31. 10.1056/NEJMoa054481 [PubMed: 17021318] [CrossRef]
3.
Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432–44. 10.1056/NEJMoa062655 [PubMed: 17021319] [CrossRef]
4.
IVAN study investigators, Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology 2012;119:1399–411. 10.1016/j.ophtha.2012.04.015 [PubMed: 22578446] [CrossRef]
5.
Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 2012;119:2537–48. 10.1016/j.ophtha.2012.09.006 [PubMed: 23084240] [CrossRef]
6.
CATT research group, Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011;364:1897–908. 10.1056/NEJMoa1102673 [PMC free article: PMC3157322] [PubMed: 21526923] [CrossRef]
7.
Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Culliford LA, et al. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet 2013;382:1258–67. 10.1016/S0140-6736(13)61501-9 [PubMed: 23870813] [CrossRef]
8.
Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, Grunwald JE, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 2012;119:1388–98. 10.1016/j.ophtha.2012.03.053 [PMC free article: PMC3389193] [PubMed: 22555112] [CrossRef]
9.
Chakravarthy U, Harding SP, Rogers CA, Downes S, Lotery AJ, Dakin H, et al. A randomised controlled trial to assess the effectiveness and cost-effectiveness of alternative treatments to Inhibit VEGF in Age-related choroidal Neovascularisation (IVAN). Health Technol Assess 2015;19(78). [PMC free article: PMC4781416] [PubMed: 26445075]
10.
Hau S, Ehrlich D, Binstead K, Verma S. An evaluation of optometrists’ ability to correctly identify and manage patients with ocular disease in the accident and emergency department of an eye hospital. Br J Ophthalmol 2007;91:437–40. 10.1136/bjo.2006.105593 [PMC free article: PMC1994753] [PubMed: 17077113] [CrossRef]
11.
Banes MJ, Culham LE, Bunce C, Xing W, Viswanathan A, Garway-Heathm D. Agreement between optometrists and ophthalmologists on clinical management decisions for patients with glaucoma. Br J Ophthalmol 2006;90:579–85. 10.1136/bjo.2005.082388 [PMC free article: PMC1857057] [PubMed: 16622087] [CrossRef]
12.
Amoaku W, Blakeney S, Freeman M, Gale R, Johnston R, Kelly SP, et al. Action on AMD. Optimising patient management: act now to ensure current and continual delivery of best possible patient care. Eye 2012;26:S2–S21. 10.1038/eye.2011.343 [PMC free article: PMC3292344] [PubMed: 22302094] [CrossRef]
13.
Kelly SP, Wallwork I, Haider D, Qureshi K. Teleophthalmology with optical coherence tomography imaging in community optometry. Evaluation of a quality improvement for macular patients. Clin Ophthalmol 2011;5:1673–8. 10.2147/OPTH.S26753 [PMC free article: PMC3236713] [PubMed: 22174576] [CrossRef]
14.
Cameron JR, Ahmed S, Curry P, Forrest G, Sanders R. Impact of direct electronic optometric referral with ocular imaging to a hospital eye service. Eye 2009;23:1134–40. 10.1038/eye.2008.196 [PubMed: 18600247] [CrossRef]
15.
Singer MA, Awh CC, Sadda S, Freeman WR, Antoszyk AN, Wong P, et al. HORIZON: An open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology 2012;119:1175–83. 10.1016/j.ophtha.2011.12.016 [PubMed: 22306121] [CrossRef]
16.
Violato M, Dakin H, Chakravarthy U, Reeves BC, Peto T, Hogg RE, et al. Cost-effectiveness of community versus hospital eye service follow-up for patients with quiescent treated age-related macular degeneration alongside the ECHoES randomised trial. BMJ Open 2016;6:e011121. 10.1136/bmjopen-2016-011121 [PMC free article: PMC5093395] [PubMed: 27797985] [CrossRef]
17.
Cochran WG, Cox MG. Experimental Designs. 2nd edn. Hoboken, NJ: John Wiley & Sons; 1992. p. 611.
18.
Fleiss JL. Balanced incomplete block-designs for interrater reliability studies. Appl Psychol Meas 1981;5:105–12. 10.1177/014662168100500115 [CrossRef]
19.
Taylor J, Scott LJ, Rogers CA, Muldrew A, O’Reilly D, Wordsworth S, et al. The design and implementation of a study to investigate the Effectiveness of Community vs. Hospital Eye Service follow-up for patients with neovascular age-related macular degeneration with quiescent disease (ECHoES) [published online ahead of print 9 October 2015]. Eye (Lond) 2015. 10.1038/eye.2015.170 [PMC free article: PMC4707499] [PubMed: 26449197] [CrossRef]
20.
National Institute for Health Research. ECHoES Trial Protocol. Health Technology Assessment programme. Southampton: National Institute for Health Research; 2013. URL: www​.nets.nihr.ac.uk/projects​/hta/11129195 (accessed 5 January 2015).
21.
National Institute for Health and Care Excellence (NICE). Guide to the Methods of Technology Appraisal 2013. London: NICE; 2013. [PubMed: 27905712]
22.
Petrou S, Gray A. Economic evaluation alongside randomised controlled trials: design, conduct, analysis, and reporting. BMJ 2011;342:d1548. 10.1136/bmj.d1548 [PMC free article: PMC3230107] [PubMed: 21474510] [CrossRef]
23.
Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. BMC Med 2013;11:80. 10.1186/1741-7015-11-80 [PMC free article: PMC3607979] [PubMed: 23531108] [CrossRef]
24.
Drummond MF, Sculpher MJ, Torrance GW, O’Brien B, Stoddart GL. Methods for the Economic Evaluation of Health Care Programmes. 3rd edn. New York, NY: Oxford University Press; 2005.
25.
Dakin HA, Wordsworth S, Rogers CA, Abangma G, Raftery J, Harding SP, et al. Cost-effectiveness of ranibizumab and bevacizumab for age-related macular degeneration: 2-year findings from the IVAN randomised trial. BMJ Open 2014;4:e005094. 10.1136/bmjopen-2014-005094 [PMC free article: PMC4120317] [PubMed: 25079928] [CrossRef]
26.
Strauss A, Corbin J. Grounded Theory Methodology: An Overview. In Denzin NK, Lincoln YS, editors. Lincoln Handbook of Qualitative Research. London: Sage; 1994. pp. 237–84.
27.
Kanski JJ, Bowling B. Clinical Ophthalmology; A Systematic Approach. Philadelphia, PA: Saunders; 2011.
28.
Joint Formulary Committee. British National Formulary (online) London: BMJ Group and Pharmaceutical Press. URL: www​.medicinescomplete.com (accessed on 12 November 2014).
29.
Curtis L. Unit Costs of Health and Social Care 2013. Canterbury: PSSRU, University of Kent; 2013.
30.
Office of National Statistics. Population of England Aged 50 Years and Over. URL: www​.ons.gov.uk/ons/rel​/snpp/sub-national-population-projections​/2012-based-projections​/rft-population-regions.xls (accessed 27 May 2015).
31.
Owen CG, Jarrar Z, Wormald R, Cook DG, Fletcher AE, Rudnicka AR. The estimated prevalence and incidence of late stage age related macular degeneration in the UK. Br J Ophthalmol 2012;96:752–6. 10.1136/bjophthalmol-2011-301109 [PMC free article: PMC3329633] [PubMed: 22329913] [CrossRef]
32.
National Institute for Health and Care Excellence (NICE). Macular Degeneration (Wet Age-Related) – Aflibercept: Costing Template. NICE TA294. URL: www​.nice.org.uk/guidance/ta294/resources (accessed 21 December 2014).
33.
Patton MQ. Qualitative Research & Evaluation Methods. 3rd edn. London: Sage Publications; 2002.
34.
Bhargava J, Bhan-Bhargava A, Foss A, King A. Views of glaucoma patients on provision of follow-up care; an assessment of patient preferences by conjoint analysis. Br J Ophthalmol 2008;92:1601–5. 10.1136/bjo.2008.140483 [PubMed: 18664502] [CrossRef]
35.
O’Connor P, Harper C, Brunton C, Clews S, Haymes S, Keeffe J. Shared care for chronic eye diseases: perspectives of ophthalmologists, optometrists and patients. Med J Aust 2012;196:646–50. 10.5694/mja11.10856 [PubMed: 22676881] [CrossRef]
36.
Burton A, Shaw R, Gibson J. ‘I’d like to know what causes it, you know, anything I’ve done?’ Are we meeting the information and support needs of patients with macular degeneration? A qualitative study. BMJ Open 2013;3:e003306. 10.1136/bmjopen-2013-003306 [PMC free article: PMC3822314] [PubMed: 24202055] [CrossRef]
37.
Mitchell J, Bradley P, Anderson S, Ffytche T, Bradley C. Perceived quality of health care in macular disease: a survey of members of the Macular Disease Society. Br J Ophthalmol 2002;86:777–81. 10.1136/bjo.86.7.777 [PMC free article: PMC1771190] [PubMed: 12084749] [CrossRef]
38.
Holtzer-Goor KM, Plochg T, Lemij HG, van Sprundel E, Koopmanschap MA, Klazinga NS. Why a successful task substitution in glaucoma care could not be transferred from a hospital setting to a primary care setting: a qualitative study. Implement Sci 2013;8:14. 10.1186/1748-5908-8-14 [PMC free article: PMC3576268] [PubMed: 23351180] [CrossRef]
39.
Gray SF, Spry PG, Brookes ST, Peters TJ, Spencer IC, Baker IA, et al. The Bristol shared care glaucoma study: outcome at follow up at 2 years. Br J Ophthalmol 2000;84:456–63. 10.1136/bjo.84.5.456 [PMC free article: PMC1723467] [PubMed: 10781507] [CrossRef]
40.
Gray SF, Spencer IC, Spry PG, Brookes ST, Baker IA, Peters TJ, et al. The Bristol shared care glaucoma study-validity of measurement and patient satisfaction. J Public Health Med 1997;19:431–6. 10.1093/oxfordjournals.pubmed.a024673 [PubMed: 9467150] [CrossRef]
41.
Konstantakopoulou E, Harper R, Edgar D, Lawrenson J. A qualitative study of stakeholder views regarding participation in locally commissioned enhanced optometric services. BMJ Open 2014;4:e00478. 10.1136/bmjopen-2013-004781 [PMC free article: PMC4039782] [PubMed: 24875489] [CrossRef]
42.
Myint J, Edgar D, Kotecha A, Murdoch I, Lawrenson J. Barriers perceived by UK-based community optometrists to the detection of primary open angle glaucoma. Ophthalmic Physiol Opt 2010;30:847–53. 10.1111/j.1475-1313.2010.00792.x [PubMed: 21205271] [CrossRef]
43.
Klein R, Klein BE, Knudtson MD, Wong TY, Cotch MF, Liu K, et al. Prevalence of age-related macular degeneration in 4 racial/ethnic groups in the multi-ethnic study of atherosclerosis. Ophthalmology 2006;113:373–80. 10.1016/j.ophtha.2005.12.013 [PubMed: 16513455] [CrossRef]
44.
Rahi J, Peckham CS, Cumberland PM. Visual impairment due to undiagnosed refractive error in working age adults in Britain. Br J Ophthalmol 2008;92:1190–4. 10.1136/bjo.2007.133454 [PubMed: 18723742] [CrossRef]
45.
Gulliford M, Dodhia H, Chamley M, McCormick K, Mohamed M, Naithani S, et al. Socio-economic and ethnic inequalities in diabetes retinal screening. Diabet Med 2010;27:282–8. 10.1111/j.1464-5491.2010.02946.x [PubMed: 20536490] [CrossRef]
46.
Wilson J, While A. Methodological issues surrounding the use of vignettes in qualitative research. J Interprof Care 1998;12:79–87. 10.3109/13561829809014090 [CrossRef]
47.
Collette JL, Childs E. Minding the gap: Meaning, affect, and the potential shortcomings of vignettes. Soc Sci Res 2011;40:513–22. 10.1016/j.ssresearch.2010.08.008 [CrossRef]
48.
Willig C. Introducing Qualitative Research in Psychology. Maidenhead: McGraw-Hill; 2008.
49.
Donaldson C, Bate A, Mitton C, Dionne F, Ruta D. Rational disinvestment. Q J Med 2010;103:801–7. 10.1093/qjmed/hcq086 [PubMed: 20530539] [CrossRef]
Copyright © Queen’s Printer and Controller of HMSO 2016. This work was produced by Reeves et al. under the terms of a commissioning contract issued by the Secretary of State for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

Included under terms of UK Non-commercial Government License.

Bookshelf ID: NBK395603
Contents

Views

  • PubReader
  • Print View
  • Cite this Page
  • PDF version of this title (15M)

Other titles in this collection

Related information

  • PMC
    PubMed Central citations
  • PubMed
    Links to PubMed

Recent Activity

ClearTurn OffTurn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...